In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

A firm handshake between proteins on immune cells is important for the body's ability to fight infection. Meanwhile, a weak ...

The development of monoclonal antibodies to molecules crucial for T-cell activation has catalyzed attempts to achieve this goal. One such molecule is the CD40L, which engages CD40 on dendritic and ...

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

What Happened: The company’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in participants ...

A firm handshake between proteins on immune cells is important for the body's ability to fight infection. Meanwhile, a weak ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

"This new anti-CD40L antibody has a great potential to be a game changer providing less toxic and more patient-friendly immunotherapy to treat diabetes and support organ/islet transplantation." ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...